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Background: This multicenter phase II study in renal transplantation compared 3 concentration-controlled ranges
of FK778 (manitimus) with mycophenolate mofetil (MMF) both given in combination with tacrolimus and
corticosteroids.
Methods: 364 patients were randomized to 12-month treatment: high-level FK778 group (H, N = 87) received
4x600mg/day (4 days) followed by 120 mg/day; mid-level FK778 group (M, N= 92) received 3x600mg/day (3 days)
followed by 110 mg/day, low-level FK778 group (L, N = 92) received 2x600mg/day (2 days) followed by 100 mg/day,
and control group received MMF 1 g/day (MMF, N = 93). After week 6, FK778 doses were adjusted to trough ranges
of 75–125 μg/mL (H), 50–100 μg/mL (M) and 25–75 μg/mL (L). Tacrolimus and steroids were administered at the
same dose in each of the 4 groups.
Results: Biopsy proven acute rejection (BPAR) at 24 weeks, the primary study endpoint, was comparable in the
L (22.8%) and MMF (17.2%) groups but higher in the H (34.5%) and M (29.3%) groups. BPAR at 12 months was
comparable in the L (23.9%) and MMF (19.4%) groups but higher in the H (34.5%) and M (31.5%) groups. Graft and
patient survival were lowest in the H group and renal function was poorest in the H and M groups. Premature
study withdrawal was highest in the H group.
Conclusions: Efficacy was similar between the low-level FK778 and MMF groups. Increased FK778 exposure was
poorly tolerated and did not improve efficacy.Background
FK778 (manitimus) is a malononitrilamide (MNA)
derived from the active leflunomide metabolite terifluno-
mide which has been found to prevent acute allograft re-
jection in multiple experimental transplantation models
in rodents, dogs, and non-human primates [1]. MNAs
suppress T-cell mediated immune reactions and directly
affect B-cell responsiveness as well as IgM and IgG anti-
body production in vitro and in vivo [2]. Of relevance to
immunosuppressed allograft recipients, moderate anti-
viral activity against cytomegalovirus (CMV) and BK
polyoma virus have been shown with leflunomide [3,4].* Correspondence: zwlodar@yahoo.co.uk
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distribution, and reproduction in any mediumMNAs have shown synergistic or additive effects when
combined with calcineurin inhibitors [5,6]. FK778 inhi-
bits dihydro-orotate dehydrogenase, interrupting de novo
pyrimidine synthesis, thereby acting on both B cells and
T cells beyond the early S phase of the cell cycle, differ-
entially from calcineurin inhibitors [6].
In a proof of concept clinical trial, renal transplant
recipients received FK778 combined with tacrolimus
and steroids. Results confirmed the immunosuppressive
activity of this combination regimen [7]. In that study,
patients received either high-dose FK778 (600 mg twice
daily for the first 2 days followed by 150 mg/day) in
combination with tacrolimus and steroids, low-dose
FK778 (600 mg/day on day 1 followed by 75 mg/day) in
combination with tacrolimus and steroids, or a combin-
ation of placebo, tacrolimus and steroids. Tacrolimus attral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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group and maintenance tacrolimus trough levels were
set at 5-15 ng/ml. Results showed comparable acute re-
jection rates at 16 weeks in the high (26.5%) and low
(25.9%) FK778 groups which were lower than rejection
rates in the placebo group (39.1%). The dosing schedule
of FK778 used in the proof of concept study yielded
FK778 levels< 100 ng/mL in many patients. However in
a subgroup of patients in which target levels of FK778
were reached by week 2, acute rejection incidence
dropped to 7.7% in the high group but remained similar
at 27.1% in the low FK778 group. Graft survival at week
16 was comparable in the high and low FK778 groups.
This study was conducted to evaluate the safety and
efficacy of three different regimens of FK778 using con-
centration controlled dosing over a 12-month period.
FK778 was combined with tacrolimus and steroids in all
3 regimens. The previous dose finding study indicated
that FK778 plasma concentrations> 100 μg/mL may be
most efficacious at preventing rejection during the first
2 weeks after transplantation. At the same time, how-
ever, those results indicated difficulty achieving recom-
mended FK778 target levels with higher dose FK778 in
the early period after transplantation suggesting that a
higher loading dose was necessary to increase the
plasma concentration. Based on this experience, this
study used concentration-controlled dosing and daily
doses were adjusted to maintain plasma concentrations
within defined ranges. The loading dose of FK778 was
increased to reach set plasma concentrations early after
transplantation and target plasma ranges of FK778 were
selected to optimize efficacy and tolerability [7]. As a
benchmark, a control regimen comprising standard
tacrolimus, mycophenolate mofetil (MMF) and steroid
regimen was used. The efficacy and safety of FK778 in
combination with tacrolimus and steroids was compared
to the control regimen.
Methods
This randomized, double-blind, 4-group, multicenter,
phase IIb study was conducted over 12 months in 37
European transplant centers. Patients were adults with
end stage kidney disease and low to medium immuno-
logical risk (PRA grade ≤ 50%), suitable candidates for
renal transplantation or re-transplantation from deceased
or living donors including donors meeting expanded
donor criteria.
Allocation to treatment was performed in a blinded
manner according to a randomization schedule provided
by the study sponsor. Randomization took place prior to
the administration of the first dose of study medication
(FK778 or MMF) and was a 1:1:1:1 randomization strati-
fied by center and donor type (living vs. deceased). Each
center was allocated a unique sequence of medicationnumbers. Investigators remained blinded to the treat-
ment randomization during the conduct of the study.
The immunosuppressive regimens and dosages were
as follows:
High level FK778: FK778 loading doses of 600 mg
given 4 times on days 1 to 4 followed by initial
doses of 120 mg/day. Targeted trough ranges were
150–200 μg/ml until week 4 and 75–125 μg/ml at week
6 and continuing for the remaining study time.
Mid level FK778: FK778 loading doses of 600 mg
given 3 times on days 1 to 3 followed by initial
doses of 110 mg/day. Targeted trough ranges were
100–150 μg/ml until week 4 and 50–100 μg/ml at week
6 and continuing for the remaining study time.
Low level FK778: FK778 loading doses of 600 mg
given 2 times on days 1 and 2 followed by initial doses
of 100 mg/day. Targeted trough ranges were
50–100 μg/ml until week 4 and 25–75 μg/ml at week
6 and continuing for the remaining study time.
MMF was administered at a starting dose of 1 g/day
given in 2 doses.
Tacrolimus was administered in all 4 treatment groups
at a dose of 0.1 mg/kg twice daily. Subsequent doses
were adjusted to achieve the following trough ranges:
10–20 ng/mL, days 0 to 30; 5–15 ng/mL, days 31 to 168;
and 5–10 ng/mL, days 169 to 365.
Corticosteroids were administered in all 4 treatment
groups as a bolus (up to 1000 mg) on day 0 and a
125 mg bolus on day 1. Starting on day 2, oral doses of
corticosteroids were tapered until day 168; doses there-
after were at the discretion of the investigator.
First line therapy for acute rejection was corticoster-
oids according to local practice. Prophylactic antiviral
treatment for CMV was required in cases of a CMV
positive donor graft and a CMV negative recipient.
The primary endpoint, the incidence of biopsy-proven
acute rejection (BPAR) confirmed by local biopsy, was
assessed at week 24.
Secondary efficacy and safety endpoints analyzed
included: incidence, time to first episode and severity of
acute rejection; incidence and time to first episode of
corticosteroid-resistant acute rejection; frequency of
treatment failure; patient and graft survival; renal func-
tion; incidence of adverse events; safety laboratory
assessments; CMV and BK polyomavirus load.
Both local and blinded central evaluations of renal biop-
sies were performed following the Banff classification [8].
Treatment failure was defined as locally evaluated BPAR,
graft loss, death, or withdrawal due to an adverse event:
the earliest date of any of these events was the date of
treatment failure. Graft loss was defined as retransplanta-
tion, nephrectomy, death or return to long-term dialysis.
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to measure chronic allograft dysfunction as an indicator
of graft outcome. Renal function was measured by serum
creatinine concentrations and calculated creatinine clear-
ance (Cockcroft-Gault formula [10]).
The sample size of 70 evaluable patients per treatment
group was considered large enough to achieve a power
of 80% based on assumed rates of patients with BPAR
within 24 weeks of 11%, 18% and 30% in the high, mid
and low level FK778 groups, respectively. Assuming a
dropout rate of 20%, 85 patients were to be enrolled in
each of the 4 treatment groups; thus, a total of at least
340 patients were to be enrolled.
The primary endpoint was analyzed using the one-
sided Cochran-Armitage trend test at a 2.5% significance
level and stratified by donor type to demonstrate an
overall positive correlation of prevention of acute rejec-
tion with increasing exposure to FK778. All statistical
testing for pair-wise comparisons was two-sided, per-
formed at the 5% level and without adjustment for mul-
tiple testing. All analyses of safety and efficacy data were
based on the intention-to-treat population (ITT) which
included all patients randomized who received at least
one dose of FK778 or MMF.
The study was conducted in compliance with the Dec-
laration of Helsinki and Good Clinical Practice guide-
lines and in accordance with local and national
regulatory requirements and laws. All relevant study
documents were approved by the Institutional Review
Board responsible for the study center. All patients pro-
vided signed informed consent and could withdraw from
the study at any time.
Results
The randomized population included 364 patients of
which 303 patients (83.2%) completed the study protocol
(Table 1). There were more patients prematurely with-
drawn from the high level FK778 group (42.5%) than fromTable 1 Disposition of Kidney Transplant Recipients Patients
Doses of FK778 or with MMF
High level FK778 Mid leve
Intent to treat population (ITT) 87 (100) 92 (
Completed study 50 (57.5) 59 (
Reasons for study withdrawal:
Death 0 1 (
Graft loss/retransplantation 1 (1.1) 1 (
Adverse event 25 (28.7) 19 (
Informed consent withdrawn 4 (4.6) 3 (
Prohibited medication 3 (3.4) 5 (
Other 4 (4.6) 4 (
Data are presented as number (percentage).the mid level FK778 group (35.9%), with a comparable per-
centage of patients withdrawn from the low level FK778
and MMF groups (22.8% and 23.7%, respectively). The ma-
jority of patients (70) were withdrawn due to adverse
events which were related to study drug dose (Table 1).
Patient baseline characteristics were well balanced
across groups with the exception of a slightly lower pro-
portion of male recipients and donors in the high level
FK778 group (Table 2). Male Caucasian patients predomi-
nated, mean age was 47, and all patients had a PRA< 50%
and were ABO compatible to their donors. Of the patients
with a recorded viral status at baseline, more than half
were CMV-positive and approximately 50% were EBV-
positive. The most common underlying pathologies lead-
ing to chronic renal failure were glomerulonephritis, poly-
cystic disease, uropathy, and nephrosclerosis.
During the first weeks after transplantation, tacrolimus
trough levels were similar across all 4 treatment groups
(Figure 1). Higher mean daily doses of tacrolimus were
required in the high and mid level FK778 groups, par-
ticularly during the first 24 weeks, to maintain targeted
tacrolimus trough levels (Figure 2).
Median FK778 trough levels were within the targeted
ranges of 150–200 μg/mL (high level FK778), 100–
150 μg/mL (mid level FK778) and 50–100 μg/mL (low
level FK778) by days 3, 4, and 5 in all dose groups and
maintained to week 4 as protocol-specified (Figure 3).
After week 4, daily doses of FK778 were reduced to at-
tain protocol-defined target trough ranges which were
maintained until month 12.
All patients in the MMF group received at least 1 g/day
of MMF by day 1 and were receiving a mean (SD) daily
dose of 1 g (0.12) at month 12.
The incidence of BPAR (local evaluation) at 24 weeks,
the study primary endpoint, was significantly higher in
the high level FK778 group than in the MMF group
(P = 0.010, Fisher’s exact test) (Table 3). The difference
in incidence between the high level FK778 and MMFreceiving Tacrolimus combined with Three Different
l FK778 Low level FK778 MMF Total
100) 92 (100) 93 (100) 364 (100)
64.1) 71 (77.2) 71 (76.3) 251 (69)
1.1) 0 0 1 (0.3)
1.1) 3 (3.3) 2 (2.2) 7 (1.9)
20.7) 14 (15.2) 12 (12.9) 70 (19.2)
3.3) 2 (2.2) 1 (1.1) 10 (2.7)
5.4) 0 1 (1.1) 9 (2.5)
4.3) 2 (2.2) 6 (6.5) 16 (4.4)
Table 2 Demographics and Transplantation Information
High level FK778 Mid level FK778 Low level FK77 MMF
N=87 N=92 N=92 N=93
Age, mean (SD), y 47.1 (11.8) 48.2 (11.9) 44.9 (12) 46.8 (12.7)
Male, % 56.3 67.4 64.1 72
Caucasian, % 96.6 94.6 96.7 95.7
Viral status, n (%):
HBV-positive 5 (5.7) 3 (3.3) 6 (6.5) 5 (5.4)
CMV-positive a 58 (66.7) 57 (62) 55 (59.8) 65 (69.9)
HCV-positive a 3 (3.4) 6 (6.5) 3 (3.3) 3 (3.2)
EBV-positive a 47 (54) 45 (48.9) 48 (52.2) 53 (57)
CMV status: donor +/recipient-, n (%) 14 (18.2) 9 (11) 14 (16.9) 11 (12.6)
First renal transplant, n (%) 82 (94.3) 85 (92.4) 82 (89.1) 87 (93.5)
Deceased donor organ, n (%) 82 (94.3) 90 (97.8) 85 (92.4) 85 (91.4)
Cold ischemia time, 15.9 (6.5) 17.2 (6.3) 16.5 (6.7) 17.1 (7.2)
mean (SD), h
Donor age, mean (SD), y 47.2 (11.2) 44.7 (13.7) 42.9 (13) 43.5 (13.7)
Male organ donor, n (%) 42 (48.3) 57 (62) 58 (63) 61 (65.6)
Mean total HLA mismatch 2.7 2.8 2.5 2.6
a Data on viral status are missing for some patients.
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tween the mid and low level FK778 groups and the
MMF group were 12.1% and 5.6%, respectively, and
did not reach statistical significance. No linear dose–
response relationship of FK778 treated groups was
found (P = 0.954; Cochran-Armitage trend test strati-
fied by donor type).
The incidence of BPAR (local evaluation) at 12 months
was highest in the high and mid level FK778 groups
(Table 3). While the incidence of corticosteroid resistant
BPAR was comparable for the FK778 treatment groups,Figure 1 Mean Tacrolimus Trough Levels during the Study presented
exception of some variability during the first weeks after transplantation, w
FK778 group, the mean tacrolimus trough levels were generally similar for
decrease in all 4 groups throughout the study.it was lower in the MMF group. The difference in inci-
dence was significantly greater in the high level FK778
group compared with the MMF group (P = 0.007, Fish-
er’s exact test). More mild (Banff I) rejections were
reported in the mid level FK778 group than in the other
groups. One severe (Banff III) rejection was reported in
the high level FK778 group.
Results of central biopsy evaluation of rejection
showed lower incidences of acute rejection in all treat-
ment groups in comparison to biopsy results of local
evaluation (Table 3).for Patients included in the Intent to Treat Population. With the
here tacrolimus levels were highest in the MMF and lowest in the high
all treatment groups. Tacrolimus trough levels showed a gradual
Figure 2 Mean Total Daily Dose (mg/kg) of Tacrolimus taken by Patients included in the Intent to Treat Population. The mean
tacrolimus dose differed across the treatment groups throughout the study being generally highest in the high level FK778 group and lowest in
the MMF group. In all treatment groups tacrolimus doses were highest during the first 3 to 4 weeks of the study and then gradually declined
throughout the study.
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BPAR (local evaluation) at 12 months were lower for the
high and mid level FK778 groups than for the low level
and MMF groups but comparable between low level
FK778 and MMF (Figure 4).
The incidence of treatment failure at 12 months was
highest in the high and mid level FK778 groups but
comparable between the low level and MMF groups
(Table 3). The primary contributor to treatment failure
was BPAR in all groups. Kaplan-Meier estimated survival
rates from treatment failure at 12 months were lowest in
the high and mid level FK778 groups (Table 3).
CADI scores did not indicate a protective effect of
FK778 against chronic allograft nephropathy. Renal
function, as measured by calculated creatinine clearance,Figure 3 Mean FK778 Trough Levels during the Study in Patients incl
trough levels were 150–200 μg/mL (high level FK778), 100 –150 μg/mL (m
achieved in all groups and maintained to week 4 as protocol-specified.was better in the MMF group compared to the high and
mid level FK778 groups. The difference in median values
between the low level FK778 and MMF groups was
minimal.
One patient in the mid level FK778 group died dur-
ing the study (death on day 4 due to cardiac arrest)
and nine patients died after premature study with-
drawal (six patients in the high and two in the low
level FK778 groups and one patient in the MMF
group). There were no statistically significant differ-
ences in patient and graft survival estimates across the
treatment groups. Patient survival at 12 months
(Kaplan Meier method) was lower for the high (88.4%)
compared to the mid (99%) and low (98%) level FK778
groups and the MMF group (99%).uded in the Intent to Treat Population. Initial target plasma FK778
id level FK778) and 50 –100 μg/mL (low level FK778), and were rapidly
Table 3 Results from the Intent to Treat Population for Primary and Secondary Efficacy Variables
High level FK778 Mid level FK778 Low level FK778 MMF
N=87 N=92 N=92 N=93
at week 24
BPAR (local evaluation), n (%) 30 (34.5) a 27 (29.3) 21 (22.8) 16 (17.2) a
at month 12
Acute rejection 35 (40.2) 32 (34.8) 32 (34.8) 21 (22.6)
BPAR (local evaluation), n (%) 30 (34.5) 29 (31.5) 22 (23.9) 18 (19.4)
Treatment outcome:
Steroid resistant 15 (17.2) b 11 (12) 10 (10.9) 4 (4.3) b
Steroid sensitive 16 (18.4) 19 (20.7) 13 (14.1) 14 (15.1)
Histological grade:
Mild (Banff I) 9 (10.3) 21 (22.8) 9 (9.8) 6 (6.5)
Moderate (Banff II) 20 (23) 8 (8.7) 13 (14.1) 12 (12.9)
Severe (Banff III) 1 (1.1) 0 0 0
Difference (CI) in BPAR: FK778 vs. MMF 0.151 0.122 0.046 –
(0.023; 0.279) (-0.003; 0.246) (-0.073; 0.164)
BPAR (central evaluation), n (%) 23 (26.4) 23 (25) 16 (17.4) 16 (17.2)
Treatment failure, n (%) 46 (52.9) 47 (51.1) 34 (37) 29 (31.2)
BPAR (local evaluation) 28 (32.2) 28 (30.4) 21 (22.8) 18 (19.4)
Graft loss 7 (8) 8 (8.7) 4 (4.3) 5 (5.4)
Withdrawal due to AE 9 (10.3) 10 (10.9) 9 (9.8) 5 (5.4)
Withdrawal due to lack of 2 (2.3) 1 (1.1) 0 1 (1.1)
efficacy
Estimated treatment failure survival rate 0.46 0.46 0.63 0.69
Estimated treatment failure survival rate: FK778 vs. MMFc 9.65 (P = 0.002) 5.66 (P = 0.017) 0.54 (P = 0.46) –
BPAR=biopsy proven acute rejection. CI= confidence interval. AE= adverse event.
a P = 0.010, Fisher’s exact test: high level FK778 vs. MMF. b P = 0.007, Fisher’s exact test: high level FK778 vs. MMF. c Chi-square test.
BPAR treatment outcomes may be reported more than once in the same patient.
Treatment failure was the first occurrence of any of these events.
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events during the study was generally comparable across
groups. At least one adverse event was reported in the
majority of patients and a causally-related adverse event
in approximately 75% of patients in each treatment
group. Adverse events leading to withdrawal were high-
est in the high and mid level FK778 groups (Table 1).
Across all treatment groups, the most common adverse
events leading to premature study withdrawal were
leukopenia (1–3.4%) and graft dysfunction (0–4.3%).
The most frequently reported adverse event regardless
of relationship to study medication was anemia (Table 4).
Adverse events associated with a significant difference
across treatment groups were thrombocytopenia, chest
pain, and hypoalbuminemia (P< 0.05, Fisher’s exact test)
(Table 4). The incidence of leucopenia, diarrhea, consti-
pation, insomnia and hyperlipidemia was lower in all
FK778 groups compared to the MMF group.
The incidence of CMV infections was 4.6% in the high
level FK778 group with a two-fold higher incidence in
the low level FK778 and MMF groups (9.8% and 10.8%,respectively). The plasma CMV DNA load and the
plasma and urine polyomavirus BK DNA load were
comparable for all treatment groups with similar use of
antiviral medication reported across groups (36–41.3%).
A malignancy was diagnosed during the study in 5
patients: 3 patients in the high level FK778 group
(adenocarcinoma [not further specified], bladder neo-
plasm, and malignant ascites), 1 patient in the mid level
FK778 group (Kaposi’s sarcoma), and 1 patient in the
MMF group (malignant neoplasm of the tongue [hist-
ology not specified]).
Mean total cholesterol and triglyceride levels were
consistently lower in the FK778 groups compared with
the MMF group. Overall, the use of lipid-lowering medi-
cations was lower in the FK778 groups (26– 28.3%)
compared to the MMF group (40%).
Discussion
The hypothesis that there is a linear dose response rela-
tionship between FK778 dose and increasing efficacy





































High level FK778 Mid level FK778
Low level FK778 MMF
Figure 4 Estimated Rate of Patients Free from Local Biopsy-proven Acute Rejection (Kaplan-Meier Method). Differences in the estimated
rate of patients free from biopsy proven acute rejection at week 24 between the high level FK778 (62.3%) vs. MMF (82%) groups were significant
(P = 0.014, Chi-square test). Differences between the two treatment groups were also significant at month 12 when estimated rates were 62.3% in
the high level FK778 vs. 79.4% in the MMF group (P = 0.023, Chi-square test).
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acute rejection rates, or less treatment failure or better
renal function. In fact, efficacy was lower in the high and
mid level FK778 groups compared with the MMF group.
In designing this study, we assumed that rates of BPAR
would be lower in the high level FK778 group (i.e., 11%)
than in the low level FK778 group (i.e., 30%). Results
showed that increasing FK778 exposure did not provide
better protection against rejection as the actual rate of
BPAR at week 24 in the high level group was three-fold
higher than the assumed rate and approximately 10%
higher than the actual BPAR rate shown with low level
FK778 exposure. Of the three FK778 regimens, low dose
FK778 demonstrated similar efficacy to a standard MMF
regimen with BPAR rates at 12 months of 23.9% versus
19.4%. The reason for higher incidences of rejection with
FK778, especially at the higher dose level, is not clear.
One possible explanation is a differential effect on differ-
ent T-cell subsets with the activity of Tregs being sup-
pressed at higher exposure to FK778.
The administration of loading doses of FK778
resulted in rapid achievement of protocol-defined
FK778 trough levels. We used loading doses which
were higher than those used in the FK778 proof of
concept study [7]. Although these higher loading doses
enabled early attainment of trough levels, the rate of
BPAR occurring during week 1 was high in both the
high and mid level FK778 treatment groups. We also
observed that while tacrolimus trough levels were
comparable across the FK778 treatment groups, higher
daily doses of tacrolimus were required, most notablyin the high level FK778 group, to achieve defined
trough ranges.
Results of several outcomes at 12 months were similar
for the low level FK778 and MMF groups. For example,
patient and graft survival rates as well as BPAR incidence
by central assessment were similar. The patient and graft
survival rates observed in the low level FK778 and MMF
groups compare well with a study in which renal trans-
plant recipients received immunosuppressive regimens of
tacrolimus, MMF, and corticosteroids or tacrolimus, siro-
limus, and corticosteroids: patient survival was greater
than 95% and graft survival was greater than 90% [11].
The incidence of treatment failure in our study was nu-
merically lower with MMF than with low level FK778
whereas renal function was found to be comparable.
The premature study withdrawal rates in the low level
FK778 and MMF treatment groups were in line with
estimated rates used for designing this study. Patient
withdrawal rates in the high and mid level FK778 groups
were higher than those assumed (20%) and were driven
primarily by large numbers of patients who withdrew
due to adverse events, notably leukopenia and graft dys-
function. The higher doses of an experimental drug may
also have played a role in premature discontinuation in
those groups. As observed in previous studies, the most
frequently reported adverse events associated with
FK778 were blood and lymphatic system disorders; the
most frequently reported single adverse event was
anemia. The incidences of chest pain, reported signifi-
cantly more frequently in the high level FK778 group
than in the other 3 groups, were investigated by three
Table 4 Most Frequently Reported Adverse Events
High level FK778 Mid level FK778 Low level FK77 MMF
N=87 N=92 N=92 N=93
Anemia 37 (42.5) 42 (45.7) 36 (39.1) 35 (37.6)
Leukopenia 7 (8) 11 (12) 6 (6.5) 13 (14)
Thrombocytopeniaa 9 (10.3) 4 (4.3) 11 (12) 2 (2.2)
Diarrhea 14 (16.1) 20 (21.7) 16 (17.4) 23 (24.7)
Constipation 15 (17.2) 8 (8.7) 7 (7.6) 17 (18.3)
Nausea 9 (10.3) 5 (5.4) 6 (6.5) 9 (9.7)
Vomiting 11 (12.6) 12 (13) 7 (7.6) 11 (11.8)
Peripheral edema 13 (14.9) 17 (18.5) 15 (16.3) 12 (12.9)
Chest painb 9 (10.3) 2 (2.2) 2 (2.2) 2 (2.2)
Bacterial urinary tract infection 19 (21.8) 29 (31.5) 28 (30.4) 27 (29)
Cytomegalovirus infection 4 (4.6) 5 (5.4) 9 (9.8) 10 (10.8)
Hypocalcaemia 13 (14.9) 13 (14.1) 12 (13) 9 (9.7)
Hyperglycemia 11 (12.6) 15 (16.3) 10 (10.9) 10 (10.8)
Hyperlipidemia 5 (5.7) 4 (4.3) 2 (2.2) 11 (11.8)
Hypokalemia 15 (17.2) 10 (10.9) 12 (13) 7 (7.5)
Hypoalbuminemiac 5 (5.7) 0 1 (1.1) 0
Hyperuricemia 9 (10.3) 21 (22.8) 20 (21.7) 12 (12.9)
Headache 11 (12.6) 11 (12) 9 (9.8) 4 (4.3)
Tremor 9 (10.3) 12 (13) 9 (9.8) 14 (15.1)
Insomnia 4 (4.6) 3 (3.3) 4 (4.3) 10 (10.8)
Hypertension 20 (23) 16 (17.4) 20 (21.7) 25 (26.9)
Data shown are for the ITT and presented as number (%). Most frequently reported adverse events occurring in ≥10% of patients in any group or occurring with a
significant difference between groups. Excluded are renal- and allograft-related adverse events.
a P = 0.02, Fisher’s exact test: high level FK778 vs. MMF; b P = 0.03, Fisher’s exact test: high level FK778 vs. MMF; c P = 0.03, Fisher’s exact test: high level FK778
vs. MMF.
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ship between FK778 administration and the events.
Previous clinical investigations showed a drop in BK
viral load following leflunomide administration [3,4] and
we expected to find lower plasma and urine polyoma-
virus BK DNA load in the FK778 treatment groups. This
was not, however, the case. Of clinical interest, FK778 at
higher doses might have provided an antiviral effect as
shown by the lower incidence of CMV infection in the
high level FK778 group compared with the other three
treatment groups.
In light of these study results and careful review of the
phase II clinical data, no clear benefit of FK778 over
current treatment options could be established. In
addition, the non-linear pharmacokinetics and the re-
quirement for intensive therapeutic drug monitoring to
optimize treatment with FK778 resulted in a decision to
discontinue its further clinical development.Conclusions
A low dose of FK778 was comparable in terms of efficacy
to a standard tacrolimus, MMF, and steroids immuno-
suppressive regimen. Increased exposure to FK778 didnot result in increased efficacy in terms of prevention of
acute rejection, treatment failure or improved renal
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